COVID-19: Drugs in Development

COVID-19: Drugs in Development

The COVID-19 outbreak, which started in December 2019 in Wuhan City, China, was declared a "Public Health Emergency of International Concern" by the WHO on January 30, 2020. The outbreak was characterized as a pandemic on March 11, 2020.

Currently, there are no drugs to treat COVID-19, caused by the novel coronavirus SARS-CoV-2.

Listed below are companies that are in the race to find a treatment or vaccine for the novel coronavirus.

Company Name Drug Current Stage Next Milestone Collaboration Last Updated

Incyte Corporation



Phase 3 trial of Olumiant in hospitalized participants with COVID-19, dubbed COV-BARRIER

Results expected in December 2020 Lilly 10/19/2020

Incyte Corporation


Jakafi Phase 3 trial of Jakafi in patients with COVID-19-associated Acute Respiratory Distress Syndrome who require mechanical ventilation (RUXCOVID-DEVENT)     10/19/2020

Relief Therapeutics Holding AG


RLF-100 US Phase 2b/3 clinical trials of RLF-100 in respiratory deficiency due to COVID-19 Topline data expected in Q4, 2020   10/13/2020
Altimmune Inc. AdCOVID Intranasal Covid-19 vaccine Positive results from the preclinical studies of AdCOVID announced on Jul.13 Phase 1 clinical trial of AdCOVID in Q4 2020 Vigene Biosciences, DynPort Vaccine Co. 10/13/2020
HUMANIGEN, INC Lenzilumab Phase III trial of Lenzilumab in severe and critical COVID-19 patients Topline data expected in Q4, 2020   10/09/2020
Hepion Pharmaceuticals, Inc. CRV431 Preclinical stage   National Institute of Allergy and Infectious Diseases 10/09/2020

Information and calendar provided by

For comments and feedback contact:

Article written by an RTT News Staff Writer, and posted on the RTT website.

Article reposted on Markethive by Jeffrey Sloe

Tagged , . Bookmark the permalink.

Leave a Reply

Your email address will not be published.